Caba stock forecast 2025 sector comparatives used in "CABA

Sector comparatives used in "CABA stock forecast 2025" place current valuation slightly below biotech median EV/EBITDA multiples. Closing this gap could elevate investor sentiment, contingent upon product pipeline activities. Institutional investors commonly compare their own returns to the returns of a commonly followed index. So they generally do consider buying larger companies that are included in the relevant benchmark index. So far this year, Intellia stock has dipped 51.3% , compared to the S&P 500 Index’s ($SPX) gain of 26.2% . For 2025, many traders project "CABA stock forecast" levels supported by historical volume spikes and biotech ETF performance. If the industry maintains its 12% CAGR, market consensus suggests price resistance near $23, assuming no major delays in product commercialization.